Jove
Visualize
Contact Us

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.3K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Glial Cells01:04

Glial Cells

92.6K
Overview
92.6K
Neural Regulation01:37

Neural Regulation

42.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K
Asymmetric Lipid Bilayer01:35

Asymmetric Lipid Bilayer

9.4K
Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...
9.4K
Membrane Lipids01:32

Membrane Lipids

33.4K
Lipids are an essential component of all biological membranes. The average lipid content in mammalian membranes is 50%, though it can be as low as 20% in the inner mitochondrial membrane or as high as 80% in the myelin sheath present around the nerve cells.
Phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and sphingomyelin are the most common phospholipids present in mammalian membranes. At physiological pH, phosphatidylserine is negatively charged, while the other three...
33.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RETRACTED: Cataldi et al. Neutral Sphingomyelinase Modulation in the Protective/Preventive Role of rMnSOD from Radiation-Induced Damage in the Brain. <i>Int. J. Mol. Sci.</i> 2019, <i>20</i>, 5431.

International journal of molecular sciences·2026
Same author

Lipidome profile of cystic fibrosis-related diabetes, type 1 and type 2 diabetes mellitus: potential links to inflammation and glucose and lipid metabolism.

American journal of physiology. Endocrinology and metabolism·2025
Same author

Sphingomyelin regulates the transcriptional machinery in nuclear lipid microdomains.

Communications biology·2025
Same author

Relationship Between Plasma Acid Sphingomyelinase and Alteration in Taste and Smell as Indicator of Long COVID in Pregnant Women.

Reports (MDPI)·2025
Same author

Depression in Adolescence: Relevance of Serotonin Receptor Polymorphisms.

Depression and anxiety·2025
Same author

Effect of Sphingomyelin and Vitamin D3 Intake on the Rabbit Brain.

International journal of molecular sciences·2025
Same journal

Explainable machine learning-based preliminary screening for viral encephalitis by blood routine analysis.

Frontiers in neurology·2026
Same journal

Global landscape of registered clinical trials of stem cell therapy for spinal cord injury: a cross-sectional analysis.

Frontiers in neurology·2026
Same journal

Experimental verification and PK/PD modeling of selective drug absorption via acupoint administration in rabbit model of rheumatoid arthritis.

Frontiers in neurology·2026
Same journal

Plasma metabolomic signatures of the no-reflow phenomenon in stroke patients following thrombectomy.

Frontiers in neurology·2026
Same journal

Parametric color-coding-derived microvascular transit time may predict infarction and reveals microcirculatory benefits of Tenecteplase in acute ischemic stroke.

Frontiers in neurology·2026
Same journal

The application of fNIRS-sEMG in the study of muscle-brain coupling.

Frontiers in neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Dec 18, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.8K

Exploring Sphingolipid Implications in Neurodegeneration.

Alice V Alessenko1, Elisabetta Albi2

  • 1Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.

Frontiers in Neurology
|June 13, 2020
PubMed
Summary
This summary is machine-generated.

Sphingolipid metabolism disruptions are key in neurodegenerative diseases like Alzheimer's and Parkinson's. Understanding these changes offers new diagnostic and therapeutic targets for brain health.

Keywords:
braindiagnostic markerneurodegenerationsphingolipidstherapeutic target

More Related Videos

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.8K
Ganglioside Extraction, Purification and Profiling
10:05

Ganglioside Extraction, Purification and Profiling

Published on: March 12, 2021

5.0K

Related Experiment Videos

Last Updated: Dec 18, 2025

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.8K
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.8K
Ganglioside Extraction, Purification and Profiling
10:05

Ganglioside Extraction, Purification and Profiling

Published on: March 12, 2021

5.0K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Cell Biology

Background:

  • Sphingolipids regulate neuronal growth, differentiation, and synaptic plasticity.
  • Maintaining sphingolipid homeostasis is crucial for preventing neurodegeneration.
  • Alterations in sphingolipid metabolism are implicated in various neurodegenerative diseases.

Purpose of the Study:

  • To review sphingolipid alterations in neurodegenerative diseases.
  • To explore the role of sphingolipids in Alzheimer's, Parkinson's, and ALS.
  • To discuss sphingolipids as potential diagnostic markers and therapeutic targets.

Main Methods:

  • Review of existing literature on sphingolipid metabolism in neurodegenerative diseases.
  • Analysis of data from animal models and human autopsy samples.
  • Examination of sphingolipids in biofluids (cerebrospinal fluid and blood).

Main Results:

  • Alzheimer's disease: Sphingolipids influence amyloid-beta processing and aggregation.
  • Parkinson's disease: Ceramide and glucocerebrosidase gene mutations are linked to alpha-synuclein aggregation and Lewy bodies.
  • Amyotrophic Lateral Sclerosis: Sphingolipid metabolism disturbances affect disease progression; fingolimod is in clinical trials.

Conclusions:

  • Sphingolipid metabolism is significantly altered in major neurodegenerative diseases.
  • These alterations present opportunities for novel diagnostic biomarkers.
  • Targeting sphingolipid pathways offers potential for innovative therapeutic strategies in neurodegenerative disorders.